Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of denosumab originator (Prolia) and biosimilar (Rukexin) with pharmacist-led education in postmenopausal osteoporosis
ChiCTR2600130225Phase 4Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of denosumab in osteoporosis (4 arms), sponsored by Peking University Third Hospital. Primary endpoints: Change rate in bone mineral density (BMD) of lumbar spine at 12 months and Proportion of patients with adherence to denosumab at 6 months. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on ChiCTR2600130225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130225.